Professional
Added to YB: 2019-10-15
Pitch date: 2019-10-15
HEMA [bullish]
HemaCare Corporation
+41.4%
current return
Author Info
1 Main Capital is a long-biased investment partnership that invests primarily in high-quality, attractively valued, growing businesses. Visit their fund website.
Company Info
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States.
Market Cap
$346.5M
Pitch Price
$17.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
50.39
EV/Sales
N/A
Sector
Health Care Providers and Services
Category
growth
1 Main Holdings position: Hemacare Corp (HEMA)
HEMA: Leading supplier of human cell material to biotech & pharma. Priced at premium due to superior quality. Revs grew $5M to $40M in 5yrs driven by cell therapy boom. 40%+ insider owned, profitable while scaling. Significant upside potential from continued growth, margin expansion, uplist & M&A.
Read full article (2 min)